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Because C. cayetanensis is a seasonal diarrheal
agent, fecal samples from persons with persistent
unexplained explosive diarrhea during the
summer should be carefully evaluated for this
infection. Stool specimens should be fixed in 10%
formalin and examined with autofluorescence
microscopy for enhanced detection.
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Partnerships for Detecting Emerging
Infectious Diseases: Nepal and Global
Influenza Surveillance
To the Editor: With new influenza strains emerging
each year, identification of circulating strains by
coordinated global surveillance is crucial to vaccine
development for the coming year (1-3). Approxi-
mately 110 laboratories in 80 countries
voluntarily participate in the World Health
Organization (WHO) influenza surveillance
network (4). Comprehensive surveillance is
especially important in Asia, since new influenza
strains often originate there. To participate in
influenza global surveillance, countries need not
rely on their own laboratory capability. Clinical
specimens from patients thought to have
influenza can be sent to designated laboratories
around the world for analysis. A unique
partnership has led to the expansion of the WHO
global influenza surveillance network to Nepal.
The U.S. Army Medical Component - Armed
Forces Research Institute for Medical Sciences
(AFRIMS) (5) in Bangkok, Thailand, is well
situated to assist with surveillance in Asia.
Scientists at AFRIMS have conducted medical
research in collaboration with Nepali colleagues
for more than 20 years. Several studies have been
conducted in collaboration with the CIWEC
Clinic Travel Medicine Center (a travel medicine
clinic that serves the diplomatic, aid, and tourist
communities in Nepal). The clinic has approxi-
mately 5,000 patient visits per year, of which half
are drawn from the 2,500 expatriates in Nepal
and half from the 200,000 non-Indian tourists
who visit Nepal annually.
A protocol was developed for a pilot influenza
surveillance program. The staff of the CIWEC
Clinic was responsible for volunteer recruitment,
clinical evaluation, and specimen collection.
Febrile upper respiratory infections were
defined as temperature ³ 100°F (37.8°C, oral or
equivalent) and cough or sore throat of  £ 72 hours
duration. Other symptoms, such as streptococcal
pharyngitis, were excluded. No age or gender
restrictions were included. Volunteers had to have
been in Nepal for the 5 days preceding illness. Only
the first patient in any single household with
similar symptoms within days of other household
members was asked to participate.
The AFRIMS field station in Kathmandu
(locally known as the Walter Reed/AFRIMS
Research Unit - Nepal or WARUN) was
responsible for shipping specimens collected by
the CIWEC Clinic to AFRIMS, Thailand. Since
dry ice was not available in Kathmandu, dry ice
and shipping containers were sent by AFRIMS,
Thailand for use by WARUN. Shipments from
WARUN were then sent back to AFRIMS, where
specimens were repacked in dry ice and sent for
testing at the central laboratory of the U.S. Air
Force’s Project Gargle (6) in San Antonio, Texas.
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specimens from distant Air Force installations for
more than 20 years. Each specimen was tested for
influenza A and B; parainfluenza virus 1, 2, and
3; adenovirus; enterovirus; and herpesvirus.
Characterization of selected influenza A and B
isolates by hemagglutination-inhibition testing
was performed by the Centers for Disease Control
and Prevention (CDC).
Between December 1996 and February 1997,
the CIWEC staff collected specimens from 18
patients. Samples were collected from 11 (61%)
residents and seven (39%) tourists, who were
evenly distributed by gender and had a median age
of 35 years. Influenza B/Beijing/184/93-like viruses
were isolated from five (28%) of the 18 specimens.
All patients from whom influenza viruses were
obtained had mild illnesses with fever and upper
respiratory syndromes. Herpes virus type 1 and
adenovirus type 6 were each identified in one other
specimen. No respiratory viruses were identified in
the remaining 11 specimens.
Because of the importance of China in the
emergence of new strains of influenza, CDC’s
WHO Collaborating Center for Surveillance,
Epidemiology, and Control of Influenza has
worked with colleagues in China to establish a
national Chinese network of influenza surveil-
lance sites. Analysis of viruses isolated in China
between 1988 and 1997 in comparison with other
viruses obtained through WHO’s global influenza
surveillance network has shown that influenza
variants are frequently identified in China before
becoming prevalent in other regions of the world.
Nepal is another especially valuable surveillance
site, given its location between China and India
(at the crossroads between northern and
southern Asia) and its historic importance as a
trans-Himalayan trade route.
Especially relevant are data from China
demonstrating that the two antigenically and
genetically distinct lineages of influenza B viruses
represented by B/Victoria/02/87 and B/Yamagata/
16/88 (7) have continued to circulate and evolve in
China, while only viruses related to B/Yamagata
have been detected elsewhere in the world and
are represented in the current trivalent vaccine
by the B/Bejing/184/93-like component. Virologic
surveillance in surrounding countries (8) such as
Nepal is necessary to detect geographic spread of
B/Victoria-like virus in the region. Our data
suggest that these viruses have not yet spread to
Kathmandu.
Our unique international partnership be-
tween several civilian and military organizations
(e.g., CIWEC Clinic, CDC, U.S. Air Force, and
U.S. Army) demonstrates the feasibility of such
partnerships as well as the usefulness of
influenza surveillance data at both the local and
global levels. Despite the small number of
isolates obtained during this study, we were able
to determine that the influenza B component of
the trivalent vaccine prepared for the 1996-1997
influenza season would likely have offered
protection for travelers and the local population
against the influenza B strains isolated in
Kathmandu. Ongoing surveillance data will
establish geographic and temporal patterns of
circulation of influenza viruses and thus
provide valuable information for guiding public
health policies for influenza vaccination. On a
global level, these data are useful for annual
vaccine strain selection.
Advances in communication, laboratory, and
specimen transport technologies contributed
greatly to the identification of viral pathogens
from a new sentinel surveillance site in Nepal. In
evaluating future collaborative sites, prior
surveillance experience and reliable specimen
shipping should be prime considerations. Ap-
proaches that use existing resources might foster
greater international cooperation toward im-
proved global detection and reporting of
infectious diseases.
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HIV-2 Infection and HIV-1/HIV-2
Dual Reactivity in Patients With
and Without AIDS-Related
Symptoms in Gabon
To the Editor: Between 1996 and 1997, we
evaluated the incidence of HIV-2 infection at the
Fondation Jeanne Ebori, the second largest
hospital in Libreville, capital of Gabon; we found
an unexpected high prevalence of HIV-2–infected
or HIV-1/HIV-2–dually reactive patients.
During a 10-month period, 147 (14.3%) of
1,029 sera from inpatients and outpatients were
found HIV-positive by the type III method
recommended by the World Health Organization
(two  enzyme-linked immunosorbent assays are
used to screen anti-HIV antibodies) (1). Further
discrimination between HIV-1 and HIV-2
infections was assessed by using synthetic
peptides specific for the gp41 and the gp120 of
HIV-1 and the gp36 of HIV-2 (ImmunoComb II,
PBS Orgenics, Illkirch, France). Of the 147 HIV-
positive sera, 141 (96.0%) were exclusively HIV-
1–positive; four were exclusively HIV-2–positive;
and two were both HIV-1– and HIV-2–positive.
Of the six sera with anti-gp36/HIV-2 reactivities,
two (from patients A and B) were positive on HIV-
2 Western blot, with marked anti-gag HIV-1
cross-reactivity and a discrimination assay
positive only for HIV-2; two (from patients D and
E) were positive on HIV-2 Western blot, with
anti-gag and pol reactivities markedly lower than
anti-env reactivities and a discrimination assay
positive only for HIV-2; the two remaining sera
(from patients C and F) showed typical dual
reactivities for HIV-1 and HIV-2 infections, with
positive patterns of HIV-1 and HIV-2 Western
blots and a discrimination test positive for both
viruses. As a whole, six (4.1%) of 147 HIV-positive
sera showed either HIV-2 infection alone (n = 4)
or dual reactivity. Of those, four were from
Gabonese patients B, C, D, and E, and two were
from immigrants from West Africa (patient A
from Mali and patient F from Nigeria); two were
female patients B and E. Among Gabonese
patients, only one (patient E) had traveled to
West Africa; the remaining three had never
visited any neighboring country. However, one
Gabonese man (patient C) lived in Port-Gentil,
which has many West African immigrants. For
all patients, the most likely risk factor for HIV
was a heterosexual relationship with an
unknown HIV-infected person. In three asymp-
tomatic patients (A, B, and C) the HIV-2–
serostatus was unexpected; in contrast, the three
other patients had AIDS-related symptoms.
Patients D and E had an HIV-2 Western blot
pattern showing a marked decrease in anti-gag
and pol reactivities compatible with their
advanced stage of HIV-2 disease.
The case of a 55-year-old exclusively
heterosexual asymptomatic woman (patient B)
suggests the possibility of a specific variant of
HIV-2 in Central Africa (2). The high frequency in
primates in Gabon of natural infection with simian
immunodeficiency retroviruses, which show a
high degree of genetic relatedness to HIV-2 (3),
could support such a hypothesis.
Two patients had typical dual reactivities to
HIV-1 and HIV-2 antigens. To our knowledge,
such dual reactivities have never been reported
in Gabon (4). In the patient from Nigeria (patient
F), the serologic pattern was typical of that
usually observed in West Africa (5). Dual
reactivity can result from genuine mixed
infections and from serologic cross-reactivity in
HIV-1 and HIV-2 infection alone; theoretically, it
could also represent infection with a different,
cross-reacting recombinant strain (5).
HIV-2 infection in Gabon is epidemiologically
related to West Africa, because of cultural and,
above all, economic ties. However, HIV-2 is not
limited to immigrant populations from West
Africa or to Gabonese citizens traveling in this
area; it has also reached the indigenous Gabonese